Funding for this research was provided by:
Princess Margaret Cancer Foundation (n/a)
Text and Data Mining valid from 2019-02-11
Received: 7 June 2018
Accepted: 17 January 2019
First Online: 11 February 2019
Com pliance with ethical standards
: Anna Spreafico has served on Advisory Boards of: MERCK, Bristol-Myers Squibb, Novartis and Oncorus. Naoto Hirano reports receiving a research grant from and is a consultant for Takara Bio. Marcus O. Butler has served on Advisory Boards of: MERCK, Bristol-Myers Squibb, Novartis, Immunocore, Immunovaccine, EMD Serono and GlaxoSmithKline. Marcus O. Butler has received funding to support investigator initiated clinical trials from MERCK and Takara Bio. All other authors declare that they have no conflict of interest.
: This study was registered on clinicatrials.gov (NCT01883323). All procedures performed in studies involving human participants were in accordance with the ethical standards of the institution (University Health Network Research Ethics Board approved protocol UHN REB# 11–0683) and/or national research committees and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: Informed consent for protocol therapy, analysis of patient samples and publication was obtained from all individual participants included in the study.